Top Five Stories of the Cellular Landscape and Therapies of Atherosclerosis: Current Knowledge and Future Perspectives

Abstract

Atherosclerosis (AS) is characterized by impairment and apoptosis of endothelial cells, continuous systemic and focal inflammation and dysfunction of vascular smooth muscle cells, which is documented as the traditional cellular paradigm. However, the mechanisms appear much more complicated than we thought since a bulk of studies on efferocytosis, transdifferentiation and novel cell death forms such as ferroptosis, pyroptosis, and extracellular trap were reported. Discovery of novel pathological cellular landscapes provides a large number of therapeutic targets. On the other side, the unsatisfactory therapeutic effects of current treatment with lipid-lowering drugs as the cornerstone also restricts the efforts to reduce global AS burden. Stem cell- or nanoparticle-based strategies spurred a lot of attention due to the attractive therapeutic effects and minimized adverse effects. Given the complexity of pathological changes of AS, attempts to develop an almighty medicine based on single mechanisms could be theoretically challenging. In this review, the top stories in the cellular landscapes during the initiation and progression of AS and the therapies were summarized in an integrated perspective to facilitate efforts to develop a multi-targets strategy and fill the gap between mechanism research and clinical translation. The future challenges and improvements were also discussed.

Keywords

atherosclerosis / transdifferentiation / extracellular traps / efferocytosis / stem cell / nanoparticles

References

[1]	Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011,473(7347):317–325
[2]	Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol, 2011,12(3):204–212
[3]	Fan J, Watanabe T. Atherosclerosis: Known and unknown. Pathol Int, 2022,72(3):151–160
[4]	Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol, 2006,47(8 Suppl):C7–12
[5]	Duan H, Zhang Q, Liu J, et al. Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis. Pharmacol Res, 2021,168:105599
[6]	Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res, 2019,124(2):315–327
[7]	Mozzini C, Garbin U, Fratta Pasini AM, et al. An exploratory look at NETosis in atherosclerosis. Intern Emerg Med, 2017,12(1):13–22
[8]	Grootaert MOJ, Moulis M, Roth L, et al. Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis. Cardiovasc Res, 2018,114(4):622–634
[9]	Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers, 2019,5(1):56
[10]	Hu MJ, Tan JS, Jiang WY, et al. The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis. Ther Adv Chronic Dis, 2022,13:20406223221078088
[11]	Chen W, Schilperoort M, Cao Y, et al. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat Rev Cardiol, 2022,19(4):228–249
[12]	Dai T, He W, Yao C, et al. Applications of inorganic nanoparticles in the diagnosis and therapy of atherosclerosis. Biomater Sci, 2020,8(14):3784–3799
[13]	Zhang N, Xie X, Chen H, et al. Stem cell-based therapies for atherosclerosis: perspectives and ongoing controversies. Stem Cells Dev, 2014,23(15):1731–1740
[14]	Glass CK and Witztum JL. Atherosclerosis. the road ahead. Cell, 2001,104(4):503–516
[15]	Rochette L, Lorin J, Zeller M, et al. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther, 2013,140(3):239–257
[16]	Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol, 2014,9:73–102
[17]	Marzolla V, Armani A, Mammi C, et al. Essential role of ICAM-1 in aldosterone-induced atherosclerosis. Int J Cardiol, 2017,232:233–242
[18]	Jia X, Bai X, Yang X, et al. VCAM-1-bmdmg peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis. Metabolism, 2022,135:155274
[19]	Georgakis MK, Bernhagen J, Heitman LH, et al. Targeting the CCL2-CCR2 axis for atheroprotection. Eur Heart J, 2022,43(19):1799–1808
[20]	Aiello RJ, Bourassa PA, Lindsey S, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 1999,19(6):1518–1525
[21]	Manta CP, Leibing T, Friedrich M, et al. Targeting of Scavenger Receptors Stabilin-1 and Stabilin-2 Ameliorates Atherosclerosis by a Plasma Proteome Switch Mediating Monocyte/Macrophage Suppression. Circulation, 2022,146(23):1783–1799
[22]	Thorp E, Subramanian M, Tabas I. The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur J Immunol, 2011,41(9):2515–2518
[23]	Myasoedova VA, Chistiakov DA, Grechko AV, et al. Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. J Mol Cell Cardiol, 2018,123:159–167
[24]	Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol, 2020,17(7):387–401
[25]	Bot I, Daissormont IT, Zernecke A, et al. CXCR4 blockade induces atherosclerosis by affecting neutrophil function. J Mol Cell Cardiol, 2014,74:44–52
[26]	Hofheinz K, Seibert F, Ackermann JA, et al. Formation of atherosclerotic lesions is independent of eosinophils in male mice. Atherosclerosis, 2020,311:67–72
[27]	Zhu J, Liu B, Wang Z, et al. Exosomes from nicotine-stimulated macrophages accelerate atherosclerosis through miR-21-3p/PTEN-mediated VSMC migration and proliferation. Theranostics, 2019,9(23):6901–6919
[28]	Monk BA, George SJ. The Effect of Ageing on Vascular Smooth Muscle Cell Behaviour— A Mini-Review. Gerontology, 2015,61(5):416–426
[29]	Bentzon JF, Otsuka F, Virmani R, et al. Mechanisms of plaque formation and rupture. Circ Res, 2014,114 (12):1852–1866
[30]	Weber C, Badimon L, Mach F, et al. Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future. Thromb Haemost, 2017,117(7):1258–1264
[31]	Ali AH, Younis N, Abdallah R, et al. Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies. Curr Med Chem, 2021,28(36):7427–7445
[32]	Pasta A, Cremonini AL, Pisciotta L, et al. PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin Pharmacother, 2020,21(3):353–363
[33]	Albers JJ, Marcovina SM, Imperatore G, et al. Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes. J Clin Endocrinol Metab, 2008,93(3):735–742
[34]	Hagensen MK, Mortensen MB, Kjolby M, et al. Increased retention of LDL from type 1 diabetic patients in atherosclerosis-prone areas of the murine arterial wall. Atherosclerosis, 2019,286:156–162
[35]	Tabit CE, Shenouda SM, Holbrook M, et al. Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation, 2013,127(1):86–95
[36]	Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 2017,377(12):1119–1131
[37]	Lv N, Zhang Y, Wang L, et al. LncRNA/CircRNA-miRNA-mRNA Axis in Atherosclerotic Inflammation: Research Progress. Curr Pharm Biotechnol, 2023, doi: https://doi.org/10.2174/0113892010267577231005102901
[38]	Cahill PA, Redmond EM. Vascular endothelium — Gatekeeper of vessel health. Atherosclerosis, 2016, 248:97–109
[39]	Lin X, Ouyang S, Zhi C, et al. Focus on ferroptosis, pyroptosis, apoptosis and autophagy of vascular endothelial cells to the strategic targets for the treatment of atherosclerosis. Arch Biochem Biophys, 2022,715:109098
[40]	Wang Y, Fan Y, Song Y, et al. Angiotensin II induces apoptosis of cardiac microvascular endothelial cells via regulating PTP1B/PI3K/Akt pathway. In Vitro Cell Dev Biol Anim, 2019,55(10):801–811
[41]	Ouyang S, You J, Zhi C, et al. Ferroptosis: the potential value target in atherosclerosis. Cell Death Dis, 2021,12(8):782
[42]	Chen X, Cai Q, Liang R, et al. Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies. Cell Death Dis, 2023,14(2):105
[43]	He B, Nie Q, Wang F, et al. Role of pyroptosis in atherosclerosis and its therapeutic implications. J Cell Physiol, 2021,236(10):7159–7175
[44]	Wang H, Liu C, Zhao Y, et al. Mitochondria regulation in ferroptosis. Eur J Cell Biol, 2020,99(1):151058
[45]	Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell, 2017, 171(2):273–285
[46]	Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol, 2021,22(4):266–282
[47]	Yang WS, Kim KJ, Gaschler MM, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A, 2016,113(34): E4966–75
[48]	Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol, 2017,13(1):91–98
[49]	Feng H, Schorpp K, Jin J, et al. Transferrin Receptor Is a Specific Ferroptosis Marker. Cell Rep, 2020,30(10):3411–3423.e7
[50]	Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature, 2019,575 (7784):693–698
[51]	Ma Y, Yi M, Wang W, et al. Oxidative degradation of dihydrofolate reductase increases CD38-mediated ferroptosis susceptibility. Cell Death Dis, 2022,13(11): 944
[52]	Kraft VAN, Bezjian CT, Pfeiffer S, et al. GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling. ACS Cent Sci, 2020,6(1):41–53
[53]	Wang Y, Zhao Y, Ye T, et al. Ferroptosis Signaling and Regulators in Atherosclerosis. Front Cell Dev Biol, 2021,9:809457
[54]	Guo Z, Ran Q, Roberts LJ2nd, et al. Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic Biol Med, 2008,44(3):343–352
[55]	Chen CJ, Huang HS, Chang WC. Inhibition of arachidonate metabolism in human epidermoid carcinoma a431 cells overexpressing phospholipid hydroperoxide glutathione peroxidase. J Biomed Sci, 2002,9(5):453–459
[56]	Gao M, Monian P, Quadri N, et al. Glutaminolysis and Transferrin Regulate Ferroptosis. Mol Cell, 2015,59(2):298–308
[57]	Mou Y, Zhang L, Liu Z, et al. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma. BMC Cancer, 2022,22(1):215
[58]	Chu B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol, 2019,21(5):579–591
[59]	Li C, Chen JW, Liu ZH, et al. CTRP5 promotes transcytosis and oxidative modification of low-density lipoprotein and the development of atherosclerosis. Atherosclerosis, 2018,278:197–209
[60]	Gao Y, Chen B, Wang R, et al. Knockdown of RRM1 in tumor cells promotes radio-/chemotherapy induced ferroptosis by regulating p53 ubiquitination and p21-GPX4 signaling axis. Cell Death Discov, 2022,8(1):343
[61]	Kang R, Kroemer G, Tang D. The tumor suppressor protein p53 and the ferroptosis network. Free Radic Biol Med, 2019,133:162–168
[62]	Zhang Q, Liu J, Duan H, et al. Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. J Adv Res, 2021,34:43–63
[63]	Linna-Kuosmanen S, Tomas Bosch V, Moreau PR, et al. NRF2 is a key regulator of endothelial microRNA expression under proatherogenic stimuli. Cardiovasc Res, 2021,117(5):1339–1357
[64]	Song X, Long D. Nrf2 and Ferroptosis: A New Research Direction for Neurodegenerative Diseases. Front Neurosci, 2020,14:267
[65]	Ruotsalainen AK, Lappalainen JP, Heiskanen E, et al. Nuclear factor E2-related factor 2 deficiency impairs atherosclerotic lesion development but promotes features of plaque instability in hypercholesterolaemic mice. Cardiovasc Res, 2019,115(1):243–254
[66]	Kerins MJ, Ooi A. The Roles of NRF2 in Modulating Cellular Iron Homeostasis. Antioxid Redox Signal, 2018,29(17):1756–1773
[67]	Murphy AJ, Sarrazy V, Wang N, et al. Deficiency of ATP-binding cassette transporter B6 in megakaryocyte progenitors accelerates atherosclerosis in mice. Arterioscler Thromb Vasc Biol, 2014,34(4):751–758
[68]	Machlus KR, Johnson KE, Kulenthirarajan R, et al. CCL5 derived from platelets increases megakaryocyte proplatelet formation. Blood, 2016,127(7):921–926
[69]	Zhou Y, Que KT, Zhang Z, et al. Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl-p53 pathway. Cancer Med, 2018,7 (8):4012–4022
[70]	Handa P, Thomas S, Morgan-Stevenson V, et al. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. J Leukoc Biol, 2019,105(5):1015–1026
[71]	Kapralov AA, Yang Q, Dar HH, et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat Chem Biol, 2020,16(3):278–290
[72]	Sampilvanjil A, Karasawa T, Yamada N, et al. Cigarette smoke extract induces ferroptosis in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol, 2020,318(3):H508–H518
[73]	Jiang QW, Kaili D, Freeman J, et al. Diabetes inhibits corneal epithelial cell migration and tight junction formation in mice and human via increasing ROS and impairing Akt signaling. Acta Pharmacol Sin, 2019,40(9):1205–1211
[74]	Feng J, Wang J, Wang Y, et al. Oxidative Stress and Lipid Peroxidation: Prospective Associations Between Ferroptosis and Delayed Wound Healing in Diabetic Ulcers. Front Cell Dev Biol, 2022,10:898657
[75]	Cheng TL, Chen PK, Huang WK, et al. Plasminogen/thrombomodulin signaling enhances VEGF expression to promote cutaneous wound healing. J Mol Med (Berl), 2018,96(12):1333–1344
[76]	Icli B, Wu W, Ozdemir D, et al. MicroRNA-615-5p Regulates Angiogenesis and Tissue Repair by Targeting AKT/eNOS (Protein Kinase B/Endothelial Nitric Oxide Synthase) Signaling in Endothelial Cells. Arterioscler Thromb Vasc Biol, 2019,39(7):1458–1474
[77]	Bai T, Li M, Liu Y, et al. Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. Free Radic Biol Med, 2020,160:92–102
[78]	Xiao FJ, Zhang D, Wu Y, et al. miRNA-17-92 protects endothelial cells from erastin-induced ferroptosis through targeting the A20–ACSL4 axis. Biochem Biophys Res Commun, 2019,515(3):448–454
[79]	You J, Ouyang S, Xie Z, et al. The suppression of hyperlipid diet-induced ferroptosis of vascular smooth muscle cells protests against atherosclerosis independent of p53/SCL7A11/GPX4 axis. J Cell Physiol, 2023,238(8):1891–1908
[80]	Liu W, ?stberg N, Yalcinkaya M, et al. Erythroid lineage Jak2V617F expression promotes atherosclerosis through erythrophagocytosis and macrophage ferroptosis. J Clin Invest, 2022,132(13):e155724
[81]	Wang Y, Tang M. PM2.5 induces ferroptosis in human endothelial cells through iron overload and redox imbalance. Environ Pollut, 2019,254(Pt A):112937
[82]	Yao X, Xie R, Cao Y, et al. Simvastatin induced ferroptosis for triple-negative breast cancer therapy. J Nanobiotechnology, 2021,19(1):311
[83]	Zhang Q, Qu H, Chen Y, et al. Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. Front Cell Dev Biol, 2022,10:806081
[84]	Jiao Y, Zhang T, Zhang C, et al. Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury. Crit Care, 2021,25(1):356\r\nRobinson KS, Toh GA, Rozario P, et al. ZAKa-driven ribotoxic stress response activates the human NLRP1 inflammasome. Science, 2022,377(6603):328–335
[85]	Yu P, Zhang X, Liu N, et al. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther, 2021,6(1):128
[86]	He X, Fan X, Bai B, et al. Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis. Pharmacol Res, 2021,165:105447
[87]	Zahid MDK, Rogowski M, Ponce C, et al. CCAAT/enhancer-binding protein beta (C/EBPβ) knockdown reduces inflammation, ER stress, and apoptosis, and promotes autophagy in oxLDL-treated RAW264.7 macrophage cells. Mol Cell Biochem, 2020,463(1–2):211–223
[88]	Chen S, Zuo Y, Huang L, et al. The MC(4) receptor agonist RO27-3225 inhibits NLRP1-dependent neuronal pyroptosis via the ASK1/JNK/p38 MAPK pathway in a mouse model of intracerebral haemorrhage. Br J Pharmacol, 2019,176(9):1341–1356
[89]	He Q, You H, Li XM, et al. HMGB1 promotes the synthesis of pro-IL-1β and pro-IL-18 by activation of p38 MAPK and NF-κB through receptors for advanced glycation end-products in macrophages. Asian Pac J Cancer Prev, 2012,13(4):1365–1370
[90]	Bai W, Huo T, Chen X, et al. Sacubitril/valsartan inhibits ox-LDL-induced MALAT1 expression, inflammation and apoptosis by suppressing the TLR4/NF-κB signaling pathway in HUVECs. Mol Med Rep, 2021,23(6):402
[91]	Zhang M, Xue Y, Chen H, et al. Resveratrol Inhibits MMP3 and MMP9 Expression and Secretion by Suppressing TLR4/NF-κB/STAT3 Activation in Ox-LDL-Treated HUVECs. Oxid Med Cell Longev, 2019,2019:9013169
[92]	Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis, 2019,10(2):128
[93]	Su J, Zhou H, Liu X, et al. oxLDL antibody inhibits MCP-1 release in monocytes/macrophages by regulating Ca(2+) /K(+) channel flow. J Cell Mol Med, 2017,21(5):929–940
[94]	Li HX, Kong FJ, Bai SZ, et al. Involvement of calcium-sensing receptor in oxLDL-induced MMP-2 production in vascular smooth muscle cells via PI3K/Akt pathway. Mol Cell Biochem, 2012,362(1–2):115–122
[95]	Zhan X, Li Q, Xu G, et al. The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors. Front Immunol, 2022,13:1109938
[96]	Zhaolin Z, Jiaojiao C, Peng W, et al. OxLDL induces vascular endothelial cell pyroptosis through miR-125a-5p/TET2 pathway. J Cell Physiol, 2019,234(5):7475–7491
[97]	Wang Y, Shi P, Chen Q, et al. Mitochondrial ROS promote macrophage pyroptosis by inducing GSDMD oxidation. J Mol Cell Biol, 2019,11(12):1069–1082
[98]	Zhang X, Zhang JH, Chen XY, et al. Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation. Antioxid Redox Signal, 2015,22(10):848–870
[99]	Yang F, Qin Y, Wang Y, et al. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. Int J Biol Sci, 2019,15(5):1010–1019
[100]	Lu Y, Lu Y, Meng J, et al. Pyroptosis and Its Regulation in Diabetic Cardiomyopathy. Front Physiol, 2021,12:791848
[101]	You L, Zheng Y, Yang J, et al. LncRNA MDRL Mitigates Atherosclerosis through miR-361/SQSTM1/NLRP3 Signaling. Mediators Inflamm, 2022,2022:5463505
[102]	Ahmadi A, Argulian E, Leipsic J, et al. From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC State-of-the-Art Review. J Am Coll Cardiol, 2019,74(12):1608–1617
[103]	Khan R, Rheaume E, Tardif JC. Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis. Curr Atheroscler Rep, 2018,20(11):53
[104]	Wu Q, He X, Wu LM, et al. MLKL Aggravates Ox-LDL-Induced Cell Pyroptosis via Activation of NLRP3 Inflammasome in Human Umbilical Vein Endothelial Cells. Inflammation, 2020,43(6):2222–2231
[105]	Huang P, Liu W, Chen J, et al. TRIM31 inhibits NLRP3 inflammasome and pyroptosis of retinal pigment epithelial cells through ubiquitination of NLRP3. Cell Biol Int, 2020,44(11):2213–2219
[106]	Chen J, Zhang C, Yan T, et al. Atorvastatin ameliorates early brain injury after subarachnoid hemorrhage via inhibition of pyroptosis and neuroinflammation. J Cell Physiol, 2021,236(10):6920–6931
[107]	Wu LM, Wu SG, Chen F, et al. Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells. Atherosclerosis, 2020,293:26–34
[108]	Ma S, Chen J, Feng J, et al. Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition. Oxid Med Cell Longev, 2018,2018:9286458
[109]	Xing SS, Yang J, Li WJ, et al. Salidroside Decreases Atherosclerosis Plaque Formation via Inhibiting Endothelial Cell Pyroptosis. Inflammation, 2020,43(2): 433–440
[110]	Han Y, Qiu H, Pei X, et al. Low-dose Sinapic Acid Abates the Pyroptosis of Macrophages by Downregulation of lncRNA-MALAT1 in Rats With Diabetic Atherosclerosis. J Cardiovasc Pharmacol, 2018,71(2):104–112
[111]	Hu Q, Zhang T, Yi L, et al. Dihydromyricetin inhibits NLRP3 inflammasome-dependent pyroptosis by activating the Nrf2 signaling pathway in vascular endothelial cells. Biofactors, 2018,44(2):123–136
[112]	Martinet W, Schrijvers DM, Herman AG, et al. z-VAD-fmk-induced non-apoptotic cell death of macrophages: possibilities and limitations for atherosclerotic plaque stabilization. Autophagy, 2006,2(4):312–314
[113]	Chen J, Jiang Y, Shi H, et al. The molecular mechanisms of copper metabolism and its roles in human diseases. Pflugers Arch, 2020,472(10):1415–1429
[114]	Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022,375(6586):1254–1261
[115]	Ruiz LM, Libedinsky A, Elorza AA. Role of Copper on Mitochondrial Function and Metabolism. Front Mol Biosci, 2021,8:711227
[116]	Zhang Z, Weichenthal S, Kwong JC, et al. A Population-Based Cohort Study of Respiratory Disease and LongTerm Exposure to Iron and Copper in Fine Particulate Air Pollution and Their Combined Impact on Reactive Oxygen Species Generation in Human Lungs. Environ Sci Technol, 2021,55(6):3807–3818
[117]	Koksal C, Ercan M, Bozkurt AK, et al. Abdominal aortic aneurysm or aortic occlusive disease: role of trace element imbalance. Angiology, 2007,58(2):191–195
[118]	Itoh S, Kim HW, Nakagawa O, et al. Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation. J Biol Chem, 2008,283(14):9157–9167
[119]	Das A, Sudhahar V, Ushio-Fukai M, et al. Novel interaction of antioxidant-1 with TRAF4: role in inflammatory responses in endothelial cells. Am J Physiol Cell Physiol, 2019,317(6):C1161–C1171
[120]	Wei H, Zhang WJ, McMillen TS, et al. Copper chelation by tetrathiomolybdate inhibits vascular inflammation and atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis, 2012,223(2):306–313
[121]	Alvarez HM, Xue Y, Robinson CD, et al. Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science, 2010,327 (5963):331–334
[122]	Vieceli Dalla Sega F, Fortini F, Aquila G, et al. Notch Signaling Regulates Immune Responses in Atherosclerosis. Front Immunol, 2019,10:1130
[123]	Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol, 2006,7(9):678–689
[124]	Li H, Zhao L, Wang T, et al. Dietary Cholesterol Supplements Disturb Copper Homeostasis in Multiple Organs in Rabbits: Aorta Copper Concentrations Negatively Correlate with the Severity of Atherosclerotic Lesions. Biol Trace Elem Res, 2022,200(1):164–171
[125]	Bügel S, Harper A, Rock E, et al. Effect of copper supplementation on indices of copper status and certain CVD risk markers in young healthy women. Br J Nutr, 2005,94(2):231–236
[126]	Fortini F, Vieceli Dalla Sega F, Caliceti C, et al. Estrogen receptor β-dependent Notchl activation protects vascular endothelium against tumor necrosis factor a (TNFa)-induced apoptosis. J Biol Chem, 2017,292(44):18178–18191
[127]	Fortini F, Vieceli Dalla Sega F, Caliceti C, et al. Estrogen-mediated protection against coronary heart disease: The role of the Notch pathway. J Steroid Biochem Mol Biol, 2019,189:87–100
[128]	Martos-Rodríguez CJ, Albarrán-Juárez J, Morales-Cano D, et al. Fibrous Caps in Atherosclerosis Form by Notch-Dependent Mechanisms Common to Arterial Media Development. Arterioscler Thromb Vasc Biol, 2021,41(9):e427–e439
[129]	Green DR. The Coming Decade of Cell Death Research: Five Riddles. Cell, 2019,177(5):1094–1107
[130]	Tao X, Wan X, Wu D, et al. A tandem activation of NLRP3 inflammasome induced by copper oxide nanoparticles and dissolved copper ion in J774A.1 macrophage. J Hazard Mater, 2021,411:125134
[131]	Mehrotra P, Ravichandran KS. Drugging the efferocytosis process: concepts and opportunities. Nat Rev Drug Discov, 2022,21(8):601–620
[132]	Pertiwi KR, de Boer OJ, Mackaaij C, et al. Extracellular traps derived from macrophages, mast cells, eosinophils and neutrophils are generated in a time-dependent manner during atherothrombosis. J Pathol, 2019,247(4):505–512
[133]	Mitra S, Deshmukh A, Sachdeva R, et al. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci, 2011,342(2):135–142
[134]	Lee C, Cheng W, Chang M, et al. Hypoxia-induced apoptosis in endothelial cells and embryonic stem cells. Apoptosis, 2005,10(4):887–894
[135]	Zhang Y, Xie Y, You S, et al. Autophagy and Apoptosis in the Response of Human Vascular Endothelial Cells to Oxidized Low-Density Lipoprotein. Cardiology, 2015,132(1):27–33
[136]	Henson PM. Cell Removal: Efferocytosis. Annu Rev Cell Dev Biol, 2017,33:127–144
[137]	Morioka S, Mauer?der C, Ravichandran KS. Living on the Edge: Efferocytosis at the Interface of Homeostasis and Pathology. Immunity, 2019,50(5):1149–1162
[138]	Lauber K, Bohn E, Kr?ber SM, et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell, 2003,113(6):717–730
[139]	Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature, 2009,461(7261):282–286
[140]	Segawa K, Kurata S, Yanagihashi Y, et al. Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science, 2014,344(6188): 1164–1168
[141]	Suzuki J, Denning DP, Imanishi E, et al. Xk-related - protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science, 2013,341(6144): 403–406
[142]	Oka K, Sawamura T, Kikuta K, et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci USA, 1998,95(16):9535–9540
[143]	Chang MK, Bergmark C, Laurila A, et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA, 1999,96(11):6353–6358
[144]	Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPa) and CD47: structure, function, and therapeutic target. Annu Rev Immunol, 2014,32:25–50
[145]	Nakahashi-Oda C, Fujiyama S, Nakazawa Y, et al. CD300a blockade enhances efferocytosis by infiltrating myeloid cells and ameliorates neuronal deficit after ischemic stroke. Sci Immunol, 2021,6(64):eabe7915
[146]	Green DR, Oguin TH, Martinez J. The clearance of dying cells: table for two. Cell Death Differ, 2016,23(6):915–926
[147]	Heckmann BL, Green DR. LC3-associated phagocytosis at a glance. J Cell Sci, 2019,132(5):jcs222984
[148]	Thorp E, Vaisar T, Subramanian M, et al. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase CS, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem, 2011,286(38):33335–33344
[149]	Komura H, Miksa M, Wu R, et al. Milk fat globule epidermal growth factor-factor VIII is down-regulated in sepsis via the lipopolysaccharide-CD14 pathway. J Immunol, 2009,182(1):581–587
[150]	Kawai T, Elliott KJ, Scalia R, et al. Contribution of ADAM17 and related ADAMs in cardiovascular diseases. Cell Mol Life Sci, 2021,78(9):4161–4187
[151]	Zhang Y, Wang Y, Zhou D, et al. Angiotensin II deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through the AT(1)R/ROS/p38 MAPK/ADAM17 pathway. Am J Physiol Cell Physiol, 2019,317(4):C776–C787
[152]	Nanda V, Downing KP, Ye J, et al. CDKN2B Regulates TGFβ Signaling and Smooth Muscle Cell Investment of Hypoxic Neovessels. Circ Res, 2016,118(2):230–240
[153]	Leeper NJ, Raiesdana A, Kojima Y, et al. Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol, 2013,33(1):e1–e10
[154]	Singla B, Lin HP, Ahn W, et al. Loss of myeloid cell-specific SIRPa, but not CD47, attenuates inflammation and suppresses atherosclerosis. Cardiovasc Res, 2022,118(15):3097–3111
[155]	Schrijvers DM, De Meyer GR, Herman AG, et al. Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res, 2007,73(3):470–480
[156]	Shaw PX, H?rkk? S, Tsimikas S, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol, 2001,21(8):1333–1339
[157]	Martinet W, Schrijvers DM, De Meyer GR. Necrotic cell death in atherosclerosis. Basic Res Cardiol, 2011,106(5):749–760
[158]	Schrijvers DM, De Meyer GR, Kockx MM, et al. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol, 2005,25(6):1256–1261
[159]	Kojima Y, Downing K, Kundu R, et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J Clin Invest, 2014,124(3):1083–1097
[160]	Proto JD, Doran AC, Gusarova G, et al. Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution. Immunity, 2018,49(4):666–677.e6
[161]	Wei YT, Wang XR, Yan C, et al. Thymosin a-l Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis. Cancer Res, 2022,82(10):1991–2002
[162]	Chen W, Li L, Wang J, et al. The ABCA1-efferocytosis axis: A new strategy to protect against atherosclerosis. Clin Chim Acta, 2021,518:1–8
[163]	Yurdagul A, Jr. Crosstalk Between Macrophages and Vascular Smooth Muscle Cells in Atherosclerotic Plaque Stability. Arterioscler Thromb Vasc Biol, 2022,42 (4):372–380
[164]	Cai B, Thorp EB, Doran AC, et al. MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J Clin Invest, 2017,127 (2):564–568
[165]	Ait-Oufella H, Kinugawa K, Zoll J, et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation, 2007, 115(16):2168–2177
[166]	Wei Y, Zhu M, Corbalán-Campos J, et al. Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of microRNA-155 on atherosclerosis. Arterioscler Thromb Vasc Biol, 2015,35(4):796–803
[167]	Khanna S, Biswas S, Shang Y, et al. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One, 2010,5(3):e9539
[168]	Mahmoudi A, Firouzjaei AA, Darijani F, et al. Effect of diabetes on efferocytosis process. Mol Biol Rep, 2022,49(11):10849–10863
[169]	Petkovic A, Erceg S, Munjas J, et al. LncRNAs as Regulators of Atherosclerotic Plaque Stability. Cells, 2023,12(14):1832
[170]	Ye ZM, Yang S, Xia YP, et al. LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation. Cell Death Dis, 2019,10(2):138
[171]	Kojima Y, Volkmer JP, McKenna K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature, 2016,536(7614):86–90
[172]	Gerlach BD, Marinello M, Heinz J, et al. Resolvin D1 promotes the targeting and clearance of necroptotic cells. Cell Death Differ, 2020,27(2):525–539
[173]	Azcutia V, Routledge M, Williams MR, et al. CD47 plays a critical role in T-cell recruitment by regulation of LFA-1 and VLA-4 integrin adhesive functions. Mol Biol Cell, 2013,24(21):3358–3368
[174]	Tosello-Trampont AC, Nakada-Tsukui K, Ravichandran KS. Engulfment of apoptotic cells is negatively regulated by Rho-mediated signaling. J Biol Chem, 2003,278(50):49911–49919
[175]	Wu DJ, Xu JZ, Wu YJ, et al. Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice. Atherosclerosis, 2009,207(1):68–73
[176]	Flores AM, Hosseini-Nassab N, Jarr KU, et al. Proefferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis. Nat Nanotechnol, 2020,15(2):154–161
[177]	D?ring Y, Soehnlein O, Weber C. Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis. Circ Res, 2017,120(4):736–743
[178]	Yipp BG, Petri B, Salina D, et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat Med, 2012,18(9):1386–1393
[179]	Pilsczek FH, Salina D, Poon KK, et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus. J Immunol, 2010,185(12):7413–7425
[180]	Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science, 2004,303(5663):1532–1535
[181]	Nakazawa D, Desai J, Steiger S, et al. Activated platelets induce MLKL-driven neutrophil necroptosis and release of neutrophil extracellular traps in venous thrombosis. Cell Death Discov, 2018,4:6
[182]	Schreiber A, Rousselle A, Becker JU, et al. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. Proc Natl Acad Sci USA, 2017,114(45):E9618–E9625
[183]	Chen KW, Monteleone M, Boucher D, et al. Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps. Sci Immunol, 2018,3(26):eaar6676
[184]	Quillard T, Araújo HA, Franck G, et al. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J, 2015,36(22):1394–1404
[185]	Pertiwi KR, van der Wal AC, Pabittei DR, et al. Neutrophil Extracellular Traps Participate in All Different Types of Thrombotic and Haemorrhagic Complications of Coronary Atherosclerosis. Thromb Haemost, 2018,118(6):1078–1087
[186]	Carmona-Rivera C, Zhao W, Yalavarthi S, et al. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis, 2015,74(7):1417–1424
[187]	D?ring Y, Manthey HD, Drechsler M, et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation, 2012,125(13):1673–1683
[188]	Chen HJ, Tas SW, de Winther MPJ. Type-I interferons in atherosclerosis. J Exp Med, 2020,217(1):e20190459
[189]	Ding X, Xiang W, He X. IFN-I Mediates Dysfunction of Endothelial Progenitor Cells in Atherosclerosis of Systemic Lupus Erythematosus. Front Immunol, 2020,11:581385
[190]	Borissoff JI, Joosen IA, Versteylen MO, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol, 2013,33(8):2032–2040
[191]	Zhai M, Gong S, Luan P, et al. Extracellular traps from activated vascular smooth muscle cells drive the progression of atherosclerosis. Nat Commun, 2022,13(1):7500
[192]	Zhang YG, Song Y, Guo XL, et al. Exosomes derived from oxLDL-stimulated macrophages induce neutrophil extracellular traps to drive atherosclerosis. Cell Cycle, 2019,18(20):2674–2684
[193]	Wang W, Jin Y, Zeng N, et al. SOD2 Facilitates the Antiviral Innate Immune Response by Scavenging Reactive Oxygen Species. Viral Immunol, 2017,30(8): 582–589
[194]	Chen L, Hu L, Li Q, et al. Exosome-encapsulated miR-505 from ox-LDL-treated vascular endothelial cells aggravates atherosclerosis by inducing NET formation. Acta Biochim Biophys Sin (Shanghai), 2019,51(12):1233–1241
[195]	Warnatsch A, Ioannou M, Wang Q, et al. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science, 2015,349(6245):316–320
[196]	Davis JC, Jr., Manzi S, Yarboro C, et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus, 1999,8(1):68–76
[197]	Li N, Zheng X, Chen M, et al. Deficient DNASE1L3 facilitates neutrophil extracellular traps-induced invasion via cyclic GMP-AMP synthase and the non-canonical NF-κB pathway in diabetic hepatocellular carcinoma. Clin Transl Immunology, 2022,11(4):e1386
[198]	Rohrbach AS, Slade DJ, Thompson PR, et al. Activation of PAD4 in NET formation. Front Immunol, 2012,3:360
[199]	Knight JS, Luo W, O’Dell AA, et al. Peptidylargmme deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res, 2014,114(6):947–956
[200]	Chen YR, Xiang XD, Sun F, et al. Simvastatin Reduces NETosis to Attenuate Severe Asthma by Inhibiting PAD4 Expression. Oxid Med Cell Longev, 2023,2023:1493684
[201]	Al-Ghoul WM, Kim MS, Fazal N, et al. Evidence for simvastatin anti-inflammatory actions based on quantitative analyses of NETosis and other inflam-mation/oxidation markers. Results Immunol, 2014,4:14–22
[202]	Huang SU, O’Sullivan KM. The Expanding Role of Extracellular Traps in Inflammation and Autoimmunity: The New Players in Casting Dark Webs. Int J Mol Sci, 2022,23(7):3793
[203]	Yousefi S, Mihalache C, Kozlowski E, et al. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ, 2009,16(11):1438–1444
[204]	Keshari RS, Jyoti A, Dubey M, et al. Cytokines induced neutrophil extracellular traps formation: implication for the inflammatory disease condition. PLoS One, 2012,7(10):e48111
[205]	Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. Front Immunol, 2012,3:380
[206]	Csomós K, Kristóf E, Jakob B, et al. Protein cross-linking by chlorinated polyamines and transglutamylation stabilizes neutrophil extracellular traps. Cell Death Dis, 2016,7(8):e2332
[207]	King PT, Sharma R, O’Sullivan K, et al. Nontypeable Haemophilus influenzae induces sustained lung oxidative stress and protease expression. PLoS One, 2015,10(3):e0120371
[208]	Liu P, Wu X, Liao C, et al. Escherichia coli and Candida albicans induced macrophage extracellular trap-like structures with limited microbicidal activity. PLoS One, 2014,9(2):e90042
[209]	King PT, Sharma R, O’Sullivan KM, et al. Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung. Sci Rep, 2017,7(1):12128
[210]	O’Sullivan KM, Lo CY, Summers SA, et al. Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. Kidney Int, 2015,88(5):1030–1046
[211]	Lauth X, von K?ckritz-Blickwede M, McNamara CW, et al. M1 protein allows Group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition. J Innate Immun, 2009,1(3):202–214
[212]	Garcia-Rodríguez KM, Bahri R, Sattentau C, et al. Human mast cells exhibit an individualized pattern of antimicrobial responses. Immun Inflamm Dis, 2020,8(2):198–210
[213]	von K?ckritz-Blickwede M, Goldmann O, Thulin P, et al. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. Blood, 2008,111(6):3070–3080
[214]	Nija RJ, Sanju S, Sidharthan N, et al. Extracellular Trap by Blood Cells: Clinical Implications. Tissue Eng Regen Med, 2020,17(2):141–153
[215]	Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol, 2011,187(1):490–500
[216]	Yousefi S, Gold JA, Andina N, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med, 2008,14(9):949–953
[217]	Ueki S, Melo RC, Ghiran I, et al. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood, 2013,121(11):2074–2083
[218]	Yousefi S, Morshed M, Amini P, et al. Basophils exhibit antibacterial activity through extracellular trap formation. Allergy, 2015,70(9):1184–1188
[219]	Loures FV, R?hm M, Lee CK, et al. Recognition of Aspergillus fumigatus hyphae by human plasmacytoid dendritic cells is mediated by dectin-2 and results in formation of extracellular traps. PLoS Pathog, 2015,11(2):e1004643
[220]	Gimbrone MA, Jr., García-Carde?a G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res, 2016,118(4):620–636
[221]	Sawma T, Shaito A, Najm N, et al. Role of RhoA and Rho-associated kinase in phenotypic switching of vascular smooth muscle cells: Implications for vascular function. Atherosclerosis, 2022,358:12–28
[222]	Miralles F, Posern G, Zaromytidou AI, et al. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell, 2003,113(3):329–342
[223]	Qi Y, Liang X, Dai F, et al. RhoA/ROCK Pathway Activation is Regulated by AT1 Receptor and Participates in Smooth Muscle Migration and Dedifferentiation via Promoting Actin Cytoskeleton Polymerization. Int J Mol Sci, 2020,21(15):5398
[224]	Kloc M, Kubiak JZ, Ghobrial RM. Macrophage-, Dendritic-, Smooth Muscle-, Endothelium-, and Stem Cells-Derived Foam Cells in Atherosclerosis. Int J Mol Sci, 2022,23(22):14154
[225]	Allahverdian S, Chehroudi AC, McManus BM, et al. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation, 2014,129(15):1551–1559
[226]	Wang Y, Dubland JA, Allahverdian S, et al. Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE (Apolipoprotein E)-Deficient Mouse Atherosclerosis. Arterioscler Thromb Vasc Biol, 2019, 39(5):876–887
[227]	Dubland JA, Francis GA. So Much Cholesterol: the unrecognized importance of smooth muscle cells in atherosclerotic foam cell formation. Curr Opin Lipidol, 2016,27(2):155–161
[228]	Costales P, Fuentes-Prior P, Castellano J, et al. K Domain CR9 of Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1) Is Critical for Aggregated LDL-induced Foam Cell Formation from Human Vascular Smooth Muscle Cells. J Biol Chem, 2015,290(24):14852–14865
[229]	Yin YW, Liao SQ, Zhang MJ, et al. TLR4-mediated inflammation promotes foam cell formation of vascular smooth muscle cell by upregulating ACAT1 expression. Cell Death Dis, 2014,5(12):e1574
[230]	Chen Z, Xue Q, Cao L, et al. Toll-Like Receptor 4 Mediated Oxidized Low-Density Lipoprotein-Induced Foam Cell Formation in Vascular Smooth Muscle Cells via Src and Sirt1/3 Pathway. Mediators Inflamm, 2021,2021:6639252
[231]	Gabunia K, Herman AB, Ray M, et al. Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL uptake in VSMC. J Mol Cell Cardiol, 2017,105:38–48
[232]	Fan Y, Zhang J, Chen CY, et al. Macrophage migration inhibitory factor triggers vascular smooth muscle cell dedifferentiation by a p68-serum response factor axis. Cardiovasc Res, 2017,113(5):519–530
[233]	Shankman LS, Gomez D, Cherepanova OA, et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med, 2015,21(6):628–637
[234]	Vendrov AE, Sumida A, Canugovi C, et al. NOXA1-dependent NADPH oxidase regulates redox signaling and phenotype of vascular smooth muscle cell during atherogenesis. Redox Biol, 2019,21:101063
[235]	Wu JH, Zhang L, Nepliouev I, et al. Drebrin attenuates atherosclerosis by limiting smooth muscle cell transdifferentiation. Cardiovasc Res, 2022,118(3):772–784
[236]	Chen C, Wang Y, Yang S, et al. MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF. J Cell Mol Med, 2015,19(5):970–985
[237]	Karolina DS, Tavintharan S, Armugam A, et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab, 2012,97(12): E2271–E2276
[238]	Zhang C, Wang X. miR-320a Targeting RGS5 Aggravates Atherosclerosis by Promoting Migration and Proliferation of ox-LDL-Stimulated Vascular Smooth Muscle Cells. J Cardiovasc Pharmacol, 2022,80(1):110–117
[239]	Haka AS, Singh RK, Grosheva I, et al. Monocyte-Derived Dendritic Cells Upregulate Extracellular Catabolism of Aggregated Low-Density Lipoprotein on Maturation, Leading to Foam Cell Formation. Arterioscler Thromb Vasc Biol, 2015,35(10):2092–2103
[240]	Stellos K, Seizer P, Bigalke B, et al. Platelet aggregates-induced human CD34+ progenitor cell proliferation and differentiation to macrophages and foam cells is mediated by stromal cell derived factor 1 in vitro. Semin Thromb Hemost, 2010,36(2):139–145
[241]	Corrêa R, Silva LFF, Ribeiro DJS, et al. Lysophosphatidylcholine Induces NLRP3 Inflammasome-Mediated Foam Cell Formation and Pyroptosis in Human Monocytes and Endothelial Cells. Front Immunol, 2019,10:2927
[242]	Tada Y, Yano S, Yamaguchi T, et al. Advanced glycation end products-induced vascular calcification is mediated by oxidative stress: functional roles of NAD(P) H-oxidase. Horm Metab Res, 2013,45(4):267–272
[243]	Goettsch C, Rauner M, Hamann C, et al. Nuclear factor of activated T cells mediates oxidised LDL-induced calcification of vascular smooth muscle cells. Diabetologia, 2011,54(10):2690–2701
[244]	Alencar GF, Owsiany KM, Karnewar S, et al. Stem Cell Pluripotency Genes Klf4 and Oct4 Regulate Complex SMC Phenotypic Changes Critical in Late-Stage Atherosclerotic Lesion Pathogenesis. Circulation, 2020,142(21):2045–2059
[245]	Parhami F, Basseri B, Hwang J, et al. High-density lipoprotein regulates calcification of vascular cells. Circ Res, 2002,91(7):570–576
[246]	Fochi S, Giuriato G, De Simone T, et al. Regulation of microRNAs in Satellite Cell Renewal, Muscle Function, Sarcopenia and the Role of Exercise. Int J Mol Sci, 2020,21(18):6732
[247]	Shanahan CM, Crouthamel MH, Kapustin A, et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res, 2011,109(6):697–711
[248]	Zhang F, Guo X, Xia Y, et al. An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis. Cell Mol Life Sci, 2021,79(1):6
[249]	Shroff RC, Shanahan CM. The vascular biology of calcification. Semin Dial, 2007,20(2):103–109
[250]	Badi I, Mancinelli L, Polizzotto A, et al. miR-34a Promotes Vascular Smooth Muscle Cell Calcification by Downregulating SIRT1 (Sirturn 1) and Axl (AXL Receptor Tyrosine Kinase). Arterioscler Thromb Vasc Biol, 2018,38(9):2079–2090
[251]	Di Bartolo BA, Schoppet M, Mattar MZ, et al. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res, 2011,91(3):537–545
[252]	Kanno Y, Into T, Lowenstein CJ, et al. Nitric oxide regulates vascular calcification by interfering with TGF- signalling. Cardiovasc Res, 2008,77(1):221–230
[253]	Oh YJ, Kim H, Kim AJ, et al. Reduction of Secreted Frizzled-Related Protein 5 Drives Vascular Calcification through Wnt3a-Mediated Rho/ROCK/JNK Signaling in Chronic Kidney Disease. Int J Mol Sci, 2020,21(10):3539
[254]	Naik V, Leaf EM, Hu JH, et al. Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study. Cardiovasc Res, 2012,94(3):545–554
[255]	Alexopoulos N, Raggi P. Calcification in atherosclerosis. Nat Rev Cardiol, 2009,6(11):681–688
[256]	Huang H, Virmani R, Younis H, et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation, 2001,103(8):1051–1056
[257]	Beckman JA, Ganz J, Creager MA, et al. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol, 2001,21(10):1618–1622
[258]	Mosseri M, Satler LF, Pichard AD, et al. Impact of vessel calcification on outcomes after coronary stenting. Cardiovasc Revasc Med, 2005,6(4):147–153
[259]	Venkitachalam L, Mackey RH, Sutton-Tyrrell K, et al. Elevated pulse wave velocity increases the odds of coronary calcification in overweight postmenopausal women. Am J Hypertens, 2007,20(5):469–475
[260]	Ramadan MM, Mahfouz EM, Gomaa GF, et al. Evaluation of coronary calcium score by multidetector computed tomography in relation to endothelial function and inflammatory markers in asymptomatic individuals. Circ J, 2008,72(5):778–785
[261]	Ehara S, Kobayashi Y, Yoshiyama M, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation, 2004,110(22):3424–3429
[262]	Motoyama S, Kondo T, Sarai M, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol, 2007,50(4):319–326
[263]	Wirka RC, Wagh D, Paik DT, et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. Nat Med, 2019,25(8):1280–1289
[264]	Miller CL, Haas U, Diaz R, et al. Coronary heart disease-associated variation in TCF21 disrupts a miR-224 binding site and miRNA-mediated regulation. PLoS Genet, 2014,10(3):e1004263
[265]	Lee HN, Choi YY, Kim JW, et al. Effect of biochemical and biomechanical factors on vascularization of kidney organoid-on-a-chip. Nano Converg, 2021,8(1):35
[266]	Chanda PK, Meng S, Lee J, et al. Nuclear S-Nitrosylation Defines an Optimal Zone for Inducing Pluripotency. Circulation, 2019,140(13):1081–1099
[267]	Hong X, Margariti A, Le Bras A, et al. Transdifferentiated Human Vascular Smooth Muscle Cells are a New Potential Cell Source for Endothelial Regeneration. Sci Rep, 2017,7(1):5590
[268]	Grootaert MOJ, Bennett MR. Vascular smooth muscle cells in atherosclerosis: time for a re-assessment. Cardiovasc Res, 2021,117(11):2326–2339
[269]	Nguyen Dinh Cat A, Briones AM, Callera GE, et al. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension, 2011,58(3):479–488
[270]	Chen PY, Qin L, Li G, et al. Smooth Muscle Cell Reprogramming in Aortic Aneurysms. Cell Stem Cell, 2020,26(4):542–557
[271]	Hergenreider E, Heydt S, Tréguer K, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol, 2012,14(3):249–356
[272]	Dong K, Shen J, He X, et al. CARMN Is an Evolutionarily Conserved Smooth Muscle Cell-Specific LncRNA That Maintains Contractile Phenotype by Binding Myocardin. Circulation, 2021,144(23):1856–1875
[273]	Hicks CW, Daya NR, Black JH,3rd, et al. Race and sex-based disparities associated with carotid endarterectomy in the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis, 2020,292:10–16
[274]	Salemi S, Prange JA, Baumgartner V, et al. Adult stem cell sources for skeletal and smooth muscle tissue engineering. Stem Cell Res Ther, 2022,13(1):156
[275]	Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science, 1999,284(5411):143–147
[276]	Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 2002,418(6893):41–49
[277]	Huang P, Wang L, Li Q, et al. Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19. Cardiovasc Res, 2020,116(2):353–367
[278]	Xiong Y, Tang R, Xu J, et al. Sequential transplantation of exosomes and mesenchymal stem cells pretreated with a combination of hypoxia and Tongxinluo efficiently facilitates cardiac repair. Stem Cell Res Ther, 2022,13(1):63
[279]	Ning Y, Huang P, Chen G, et al. Atorvastatin-pretreated mesenchymal stem cell-derived extracellular vesicles promote cardiac repair after myocardial infarction via shifting macrophage polarization by targeting microRNA-139-3p/Stat1 pathway. BMC Med, 2023,21 (1):96
[280]	George J, Afek A, Abashidze A, et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol, 2005,25(12):2636–2641
[281]	Tousoulis D, Briasoulis A, Vogiatzi G, et al. Infusion of lin-/sca-1+ and endothelial progenitor cells improves proinflammatory and oxidative stress markers in atherosclerotic mice. Int J Cardiol, 2013,167(5):1900–1905
[282]	Wei X, Sun G, Zhao X, et al. Human amnion mesenchymal stem cells attenuate atherosclerosis by modulating macrophage function to reduce immune response. Int J Mol Med, 2019,44(4):1425–1435
[283]	Li Q, Sun W, Wang X, et al. Skin-Derived Mesenchymal Stem Cells Alleviate Atherosclerosis via Modulating Macrophage Function. Stem Cells Transl Med, 2015,4(11):1294–1301
[284]	Wang SS, Hu SW, Zhang QH, et al. Mesenchymal Stem Cells Stabilize Atherosclerotic Vulnerable Plaque by Anti-Inflammatory Properties. PLoS One, 2015,10(8):e0136026
[285]	Frodermann V, van Duijn J, van Pel M, et al. Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development. Sci Rep, 2015,5:15559
[286]	Mu Y, Xu W, Liu J, et al. Mesenchymal stem cells moderate experimental autoimmune uveitis by dynamic regulating Th17 and Breg cells response. J Tissue Eng Regen Med, 2022,16(1):26–35
[287]	Zhang X, Huang F, Li W, et al. Human Gingiva-Derived Mesenchymal Stem Cells Modulate Monocytes/Macrophages and Alleviate Atherosclerosis. Front Immunol, 2018,9:878
[288]	Li JZ, Cao TH, Han JC, et al. Comparison of adipose- and bone marrow-derived stem cells in protecting against ox-LDL-induced inflammation in M1-macrophage-derived foam cells. Mol Med Rep, 2019,19(4):2660–2670
[289]	Hong R, Wang Z, Sui A, et al. Gingival mesenchymal stem cells attenuate pro-inflammatory macrophages stimulated with oxidized low-density lipoprotein and modulate lipid metabolism. Arch Oral Biol, 2019,98:92–98
[290]	Sharma M, Schlegel MP, Afonso MS, et al. Regulatory T Cells License Macrophage Pro-Resolving Functions During Atherosclerosis Regression. Circ Res, 2020,127 (3):335–353
[291]	Fazio S, Babaev VR, Murray AB, et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA, 1997,94(9):4647–4652
[292]	Van Eck M, Herijgers N, Vidgeon-Hart M, et al. Accelerated atherosclerosis in C57Bl/6 mice transplanted with ApoE-deficient bone marrow. Atherosclerosis, 2000,150(1):71–80
[293]	Yu B, Chen Q, Le Bras A, et al. Vascular Stem/Progenitor Cell Migration and Differentiation in Atherosclerosis. Antioxid Redox Signal, 2018,29(2):219–235
[294]	Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation, 2003,108(4):457–463
[295]	Zhang Z, Li Z, Wang Y, et al. PDGF-BB/SA/Dex injectable hydrogels accelerate BMSC-mediated functional full thickness skin wound repair by promoting angiogenesis. J Mater Chem B, 2021,9(31):6176–6189
[296]	Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science, 1995,267 (5200):1034–1037
[297]	Herijgers N, Van Eck M, Groot PH, et al. Effect of bone marrow transplantation on lipoprotein metabolism and atherosclerosis in LDL receptor-knockout mice. Arterioscler Thromb Vasc Biol, 1997,17(10):1995–2003
[298]	Nelson WD, Zenovich AG, Ott HC, et al. Sex-dependent attenuation of plaque growth after treatment with bone marrow mononuclear cells. Circ Res, 2007,101(12):1319–1327
[299]	Li Y, Shi G, Han Y, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells on aortic atherosclerotic plaque in a high-fat diet rabbit model. Stem Cell Res Ther, 2021,12(1):407
[300]	Bromage DI, Davidson SM, Yellon DM. Stromal derived factor la: a chemokine that delivers a two-pronged defence of the myocardium. Pharmacol Ther, 2014,143(3):305–315
[301]	Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep, 2009,61(1):22–32
[302]	Merckelbach S, van der Vorst EPC, Kallmayer M, et al. Expression and Cellular Localization of CXCR4 and CXCL12 in Human Carotid Atherosclerotic Plaques. Thromb Haemost, 2018,118(1):195–206
[303]	Chatterjee M, von Ungern-Sternberg SN, Seizer P, et al. Platelet-derived CXCL12 regulates monocyte function, survival, differentiation into macrophages and foam cells through differential involvement of CXCR4-CXCR7. Cell Death Dis, 2015,6(11):e1989
[304]	Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation, 2006,114(14):1504–1511
[305]	Hassanzadeh A, Shamlou S, Yousefi N, et al. Genetically-modified Stem Cell in Regenerative Medicine and Cancer Therapy; A New Era. Curr Gene Ther, 2022,22(1):23–39
[306]	Cheng G, Wang X, Li Y, et al. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling. Stem Cell Res Ther, 2017,8(1):34
[307]	Tao X, Sun M, Chen M, et al. HMGB1-modified mesenchymal stem cells attenuate radiation-induced vascular injury possibly via their high motility and facilitation of endothelial differentiation. Stem Cell Res Ther, 2019,10(1):92
[308]	Tian XQ, Yang YJ, Li Q, et al. Combined therapy with atorvastatin and atorvastatin-pretreated mesenchymal stem cells enhances cardiac performance after acute myocardial infarction by activating SDF-1/CXCR4 axis. Am J Transl Res, 2019,11(7):4214–4231
[309]	Shafei AE, Ali MA, Ghanem HG, et al. Mesenchymal stem cell therapy: A promising cell-based therapy for treatment of myocardial infarction. J Gene Med, 2017,19(12). doi: https://doi.org/10.1002/jgm.2995
[310]	Maeda T, Mandai M, Sugita S, et al. Strategies of pluripotent stem cell-based therapy for retinal degeneration: update and challenges. Trends Mol Med, 2022,28(5):388–404
[311]	Lin Y, Liu M, Chen E, et al. Bone marrow-derived mesenchymal stem cells microvesicles stabilize atherosclerotic plaques by inhibiting NLRP3-mediated macrophage pyroptosis. Cell Biol Int, 2021,45(4):820–830
[312]	Gao H, Yu Z, Li Y, et al. miR-100-5p in human umbilical cord mesenchymal stem cell-derived exosomes mediates eosinophilic inflammation to alleviate atherosclerosis via the FZD5/Wnt/β-catenin pathway. Acta Biochim Biophys Sin (Shanghai), 2021,53(9):1166–1176
[313]	Ma J, Chen L, Zhu X, et al. Mesenchymal stem cell-derived exosomal miR-21a-5p promotes M2 macrophage polarization and reduces macrophage infiltration to attenuate atherosclerosis. Acta Biochim Biophys Sin (Shanghai), 2021,53(9):1227–1236
[314]	Yang W, Yin R, Zhu X, et al. Mesenchymal stem-cell-derived exosomal miR-145 inhibits atherosclerosis by targeting JAM-A. Mol Ther Nucleic Acids, 2021,23:119–131
[315]	Xiao X, Xu M, Yu H, et al. Mesenchymal stem cell-derived small extracellular vesicles mitigate oxidative stress-induced senescence in endothelial cells via regulation of miR-146a/Src. Signal Transduct Target Ther, 2021,6(1):354
[316]	Emini Veseli B, Perrotta P, De Meyer GRA, et al. Animal models of atherosclerosis. Eur J Pharmacol, 2017,816:3–13
[317]	Pan Q, Xu J, Wen CJ, et al. Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction. Int J Nanomedicine, 2021,16:6719–6747
[318]	Pechanova O, Barta A, Koneracka M, et al. Protective Effects of Nanoparticle-Loaded Aliskiren on Cardiovascular System in Spontaneously Hypertensive Rats. Molecules, 2019,24(15):2710
[319]	Yuan LF, Sheng J, Lu P, et al. Nanoparticle-mediated RNA interference of angiotensinogen decreases blood pressure and improves myocardial remodeling in spontaneously hypertensive rats. Mol Med Rep, 2015,12(3):4657–4663
[320]	Czyzynska-Cichon I, Janik-Hazuka M, Szafraniec-Szcz?sny J, et al. Low Dose Curcumin Administered in Hyaluronic Acid-Based Nanocapsules Induces Hypotensive Effect in Hypertensive Rats. Int J Nanomedicine, 2021,16:1377–1390
[321]	Martín Giménez VM, Díaz-Rodríguez P, Sanz RL, et al. Anandamide-nanoformulation obtained by electrospraying for cardiovascular therapy. Int J Pharm, 2019,566:1–10
[322]	Jin Y, Song Y, Zhu X, et al. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials, 2012,33(5):1573–1582
[323]	Hasan AA, Madkor H, Wageh S. Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug Deliv, 2013,20(3–4):120–126
[324]	Mao Y, Hu Y, Feng W, et al. Effects and mechanisms of PSS-loaded nanoparticles on coronary microcirculation dysfunction in streptozotocin-induced diabetic cardio-myopathy rats. Biomed Pharmacother, 2020,121:109280
[325]	Chen Y, Zeng Y, Zhu X, et al. Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment. Bioact Mater, 2021,6(3):880–889
[326]	Ahn S, Lee IH, Lee E, et al. Oral delivery of an antidiabetic peptide drug via conjugation and complexation with low molecular weight chitosan. J Control Release, 2013,170(2):226–232
[327]	Boada C, Zinger A, Tsao C, et al. Rapamycin-Loaded Biomimetic Nanoparticles Reverse Vascular Inflammation. Circ Res, 2020,126(1):25–37
[328]	Ma S, Tian XY, Zhang Y, et al. E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis. Sci Rep, 2016,6:22910
[329]	Seijkens TTP, van Tiel CM, Kusters PJH, et al. Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. J Am Coll Cardiol, 2018,71(5):527–542
[330]	Ji J, Yang JA, He X, et al. Cardiac-targeting transfection of tissue-type plasminogen activator gene to prevent the graft thrombosis and vascular anastomotic restenosis after coronary bypass. Thromb Res, 2014,134(2):440–448
[331]	Pan H, Palekar RU, Hou KK, et al. Anti-JNK2 peptide-siRNA nanostructures improve plaque endothelium and reduce thrombotic risk in atherosclerotic mice. Int J Nanomedicine, 2018,13:5187–5205
[332]	Sager HB, Dutta P, Dahlman JE, et al. RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med, 2016,8(342):342ra80
[333]	Di Francesco V, Gurgone D, Palomba R, et al. Modulating Lipoprotein Transcellular Transport and Atherosclerotic Plaque Formation in ApoE(–/–) Mice via Nanoformulated Lipid-Methotrexate Conjugates. ACS Appl Mater Interfaces, 2020,12(34):37943–37956
[334]	Mishra S, Bedja D, Amuzie C, et al. Improved intervention of atherosclerosis and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor. Biomaterials, 2015,64:125–135
[335]	Barbieri LR, Louren?o-Filho DD, Tavares ER, et al. Influence of Drugs Carried in Lipid Nanoparticles in Coronary Disease of Rabbit Transplanted Heart. Ann Thorac Surg, 2017,104(2):577–583
[336]	Gomes FLT, Maranh?o RC, Tavares ER, et al. Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy With Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles. J Cardiovasc Pharmacol Ther, 2018,23(6):561–569
[337]	Daminelli EN, Martinelli AE, Bulgarelli A, et al. Reduction of Atherosclerotic Lesions by the Chemotherapeutic Agent Carmustine Associated to Lipid Nanoparticles. Cardiovasc Drugs Ther, 2016,30(5):433–443
[338]	Ning B, Chen Y, Waqar AB, et al. Hypertension Enhances Advanced Atherosclerosis and Induces Cardiac Death in Watanabe Heritable Hyperlipidemic Rabbits. Am J Pathol, 2018,188(12):2936–2947
[339]	Mair KM, Robinson E, Kane KA, et al. Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br J Pharmacol, 2010,161(1):176–192
[340]	Wu ZH, Ping QN, Wei Y, et al. Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharmacol Sin, 2004,25(7):966–972
[341]	García-Díaz M, Foged C, Nielsen HM. Improved insulin loading in poly(lactic-co-glycolic) acid (PLGA) nanoparticles upon self-assembly with lipids. Int J Pharm, 2015,482(1–2):84–91
[342]	Luo XM, Yan C, Feng YM. Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis. Adv Drug Deliv Rev, 2021,172:234–248
[343]	Nakashiro S, Matoba T, Umezu R, et al. Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE–/–Mice. Arterioscler Thromb Vasc Biol, 2016,36(3):491–500
[344]	Aillon KL, Xie Y, El-Gendy N, et al. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev, 2009,61(6):457–466
[345]	Markovsky E, Baabur-Cohen H, Eldar-Boock A, et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release, 2012, 161(2):446–460
[346]	Feng L, Yang X, Liang S, et al. Silica nanoparticles trigger the vascular endothelial dysfunction and prethrombotic state via miR-451 directly regulating the IL6R signaling pathway. Part Fibre Toxicol, 2019,16(1):16
[347]	Duan J, Yu Y, Yu Y, et al. Silica nanoparticles enhance autophagic activity, disturb endothelial cell homeostasis and impair angiogenesis. Part Fibre Toxicol, 2014,11:50
[348]	Duan J, Liang S, Yu Y, et al. Inflammation-coagulation response and thrombotic effects induced by silica nanoparticles in zebrafish embryos. Nanotoxicology, 2018,12(5):470–484
[349]	Maranh?o RC, Guido MC, de Lima AD, et al. Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats. Int J Nanomedicine, 2017,12:3767–3784
[350]	Dong Z, Guo J, Xing X, et al. RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model. Biomed Pharmacother, 2017,89:297–304
[351]	Nemmar A, Beegam S, Yuvaraju P, et al. Ultrasmall superparamagnetic iron oxide nanoparticles acutely promote thrombosis and cardiac oxidative stress and DNA damage in mice. Part Fibre Toxicol, 2016,13(1):22
[352]	El-Hussainy el HM, Hussein AM, Abdel-Aziz A, et al. Effects of aluminum oxide (Al2O3) nanoparticles on ECG, myocardial inflammatory cytokines, redox state, and connexin 43 and lipid profile in rats: possible cardioprotective effect of gallic acid. Can J Physiol Pharmacol, 2016,94(8):868–878
[353]	Guo B, Yang F, Zhang L, et al. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with aPD-Ll for Enhanced Cancer Immunotherapy. Adv Mater, 2023,35(22):e2212267
[354]	Chen W, Li D. Reactive Oxygen Species (ROS)-Responsive Nanomedicine for Solving Ischemia-Reperfusion Injury. Front Chem, 2020,8:732
[355]	Deng Z, Liu S. Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases. Drug Deliv Transl Res, 2021,11(4):1475–1497\r\nHu S, Wang X, Li Z, et al. Platelet membrane and stem cell exosome hybrid enhances cellular uptake and targeting to heart injury. Nano Today, 2021,39:101210
[356]	Liang D, Feng Y, Zandkarimi F, et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell, 2023,86(13):2748–2764.e22
[357]	Yalcinkaya M, Fotakis P, Liu W, et al. Cholesterol accumulation in macrophages drives NETosis in atherosclerotic plaques via IL-lβ secretion. Cardiovasc Res, 2023,119(4):969–981
[358]	Libby P. The changing landscape of atherosclerosis. Nature, 2021,592(7855):524–533
[359]	van Hasselt JGC, Iyengar R. Systems Pharmacology: Defining the Interactions of Drug Combinations. Annu Rev Pharmacol Toxicol, 2019,59:21–40
[360]	Gupta V, Datta P. Next-generation strategy for treating drug resistant bacteria: Antibiotic hybrids. Indian J Med Res, 2019,149(2):97–106